MPT-0118 will be administered orally twice daily (BID). Pembrolizumab will be administered intravenously (IV) at a dose of 200 mg every 3 weeks.
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors.~The study will be conducted in 3 parts:~Part A: MPT-0118 dose-escalation~Part B: MPT-0118 dose-escalation in combination with pembrolizumab~Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab